$GLUE
Monte Rosa Therapeutics, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024093296 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $9.216M $4.695M
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.127M $9.282M
YoY Change -6.15% 13.96%
% of Gross Profit
Research & Development $27.62M $28.06M
YoY Change -2.44% -3.51%
% of Gross Profit
Depreciation & Amortization $2.103M $2.060M
YoY Change 14.67% 48.09%
% of Gross Profit
Operating Expenses $35.74M $37.34M
YoY Change -3.31% 0.31%
Operating Profit -$26.53M -$32.64M
YoY Change -28.24% -12.3%
Interest Expense $2.892M $2.637M
YoY Change 29.86% 14.55%
% of Operating Profit
Other Income/Expense, Net $2.739M $2.584M
YoY Change 21.52% 15.72%
Pretax Income -$23.79M -$30.06M
YoY Change -31.47% -14.09%
Income Tax $71.00K $252.0K
% Of Pretax Income
Net Earnings -$23.86M -$30.31M
YoY Change -31.6% -13.84%
Net Earnings / Revenue -258.89% -645.58%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.29 -$0.43
COMMON SHARES
Basic Shares Outstanding 61.37M 50.51M
Diluted Shares Outstanding 82.01M 71.23M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $242.2M $262.2M
YoY Change 35.7% 29.12%
Cash & Equivalents $125.6M $108.8M
Short-Term Investments $116.6M $153.4M
Other Short-Term Assets $8.426M $5.849M
YoY Change 105.51% 50.59%
Inventory
Prepaid Expenses
Receivables $9.000M
Other Receivables $842.0K
Total Short-Term Assets $251.2M $277.9M
YoY Change 37.34% 33.54%
LONG-TERM ASSETS
Property, Plant & Equipment $31.44M $33.25M
YoY Change -10.15% -5.9%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $159.0K $209.0K
YoY Change -41.11% -28.18%
Total Long-Term Assets $63.87M $66.22M
YoY Change -7.69% -6.09%
TOTAL ASSETS
Total Short-Term Assets $251.2M $277.9M
Total Long-Term Assets $63.87M $66.22M
Total Assets $315.1M $344.1M
YoY Change 24.98% 23.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.978M $6.473M
YoY Change -27.67% 21.95%
Accrued Expenses $18.75M $16.23M
YoY Change 9.62% 17.77%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $41.64M $42.35M
YoY Change 84.18% 121.85%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $67.98M $77.10M
YoY Change 51.07% 68.06%
Total Long-Term Liabilities $67.98M $77.10M
YoY Change 51.07% 68.06%
TOTAL LIABILITIES
Total Short-Term Liabilities $41.64M $42.35M
Total Long-Term Liabilities $67.98M $77.10M
Total Liabilities $109.6M $119.4M
YoY Change 62.21% 83.87%
SHAREHOLDERS EQUITY
Retained Earnings -$452.0M -$428.2M
YoY Change 35.9% 43.79%
Common Stock $659.8M $655.5M
YoY Change 27.22% 27.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $205.5M $224.7M
YoY Change
Total Liabilities & Shareholders Equity $315.1M $344.1M
YoY Change 24.98% 23.51%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$23.86M -$30.31M
YoY Change -31.6% -13.84%
Depreciation, Depletion And Amortization $2.103M $2.060M
YoY Change 14.67% 48.09%
Cash From Operating Activities -$20.99M -$27.77M
YoY Change -15.04% 9.65%
INVESTING ACTIVITIES
Capital Expenditures $399.0K $2.022M
YoY Change -75.96% -68.95%
Acquisitions
YoY Change
Other Investing Activities $38.15M -$59.14M
YoY Change 2.3% -335.96%
Cash From Investing Activities $37.75M -$61.16M
YoY Change 5.98% -429.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 15.00K 98.02M
YoY Change -98.64% 8068.58%
NET CHANGE
Cash From Operating Activities -20.99M -27.77M
Cash From Investing Activities 37.75M -61.16M
Cash From Financing Activities 15.00K 98.02M
Net Change In Cash 16.77M 9.098M
YoY Change 39.63% -263.22%
FREE CASH FLOW
Cash From Operating Activities -$20.99M -$27.77M
Capital Expenditures $399.0K $2.022M
Free Cash Flow -$21.39M -$29.79M
YoY Change -18.87% -6.43%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Net Income Loss
NetIncomeLoss
-62278000
us-gaap Net Income Loss
NetIncomeLoss
-67216000
CY2024Q2 us-gaap Pension Expense
PensionExpense
261000
CY2023Q2 us-gaap Pension Expense
PensionExpense
235000
us-gaap Pension Expense
PensionExpense
543000
us-gaap Pension Expense
PensionExpense
451000
us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
1
us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.04
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001826457
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40522
dei Entity Registrant Name
EntityRegistrantName
Monte Rosa Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3766197
dei Entity Address Address Line1
EntityAddressAddressLine1
321 Harrison Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 900
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02118
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
949-2643
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
GLUE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
61372824
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
108847000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
128101000
CY2024Q2 us-gaap Marketable Securities
MarketableSecurities
153358000
CY2023Q4 us-gaap Marketable Securities
MarketableSecurities
104312000
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9000000
CY2024Q2 us-gaap Other Receivables
OtherReceivables
842000
CY2023Q4 us-gaap Other Receivables
OtherReceivables
505000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5849000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3294000
CY2024Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.43
CY2024Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.43
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.71
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.71
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.95
CY2024Q2 us-gaap Assets Current
AssetsCurrent
277896000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
236212000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33250000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33803000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
27893000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
28808000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4866000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4580000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
209000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
352000
CY2024Q2 us-gaap Assets
Assets
344114000
CY2023Q4 us-gaap Assets
Assets
303755000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
6473000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
11152000
CY2024Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
12759000
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
14600000
CY2024Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
19645000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
17678000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3471000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3162000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
42348000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
46592000
CY2024Q2 us-gaap Deferred Revenue
DeferredRevenue
33596000
CY2023Q4 us-gaap Deferred Revenue
DeferredRevenue
32323000
CY2024Q2 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
2614000
CY2023Q4 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
2713000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
40885000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
42877000
CY2024Q2 us-gaap Liabilities
Liabilities
119443000
CY2023Q4 us-gaap Liabilities
Liabilities
124505000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
61333597
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
61328282
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50154929
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50140233
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
6000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
655501000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
547857000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2670000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2724000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-428166000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-365888000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
224671000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
179250000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
344114000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
303755000
CY2024Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
4695000
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
5759000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28055000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29076000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
55081000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
55831000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9282000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8145000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18267000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15649000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
37337000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
37221000
us-gaap Operating Expenses
OperatingExpenses
73348000
us-gaap Operating Expenses
OperatingExpenses
71480000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-32642000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-37221000
us-gaap Operating Income Loss
OperatingIncomeLoss
-67589000
us-gaap Operating Income Loss
OperatingIncomeLoss
-71480000
CY2024Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2637000
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2302000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
5079000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4739000
CY2024Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-53000
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-93000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
567000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-178000
CY2024Q2 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
CY2023Q2 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
24000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
24000
CY2024Q2 glue Gain Loss On Marketable Securities
GainLossOnMarketableSecurities
0
CY2023Q2 glue Gain Loss On Marketable Securities
GainLossOnMarketableSecurities
0
glue Gain Loss On Marketable Securities
GainLossOnMarketableSecurities
0
glue Gain Loss On Marketable Securities
GainLossOnMarketableSecurities
-131000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2584000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2233000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5646000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4454000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30058000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34988000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-61943000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-67026000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
252000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
190000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
335000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
190000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-30310000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-35178000
us-gaap Net Income Loss
NetIncomeLoss
-62278000
us-gaap Net Income Loss
NetIncomeLoss
-67216000
CY2024Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.43
CY2024Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.43
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.71
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.71
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.95
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.95
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.36
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.36
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
71233992
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71233992
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49431922
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49431922
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65695095
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65695095
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49389931
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49389931
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-30310000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-35178000
us-gaap Net Income Loss
NetIncomeLoss
-62278000
us-gaap Net Income Loss
NetIncomeLoss
-67216000
CY2024Q2 glue Provision For Pension Benefit Obligation
ProvisionForPensionBenefitObligation
35000
CY2023Q2 glue Provision For Pension Benefit Obligation
ProvisionForPensionBenefitObligation
14000
glue Provision For Pension Benefit Obligation
ProvisionForPensionBenefitObligation
70000
glue Provision For Pension Benefit Obligation
ProvisionForPensionBenefitObligation
28000
CY2024Q2 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
12000
CY2023Q2 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
261000
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
16000
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
-84000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30287000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35425000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-62224000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-67104000
CY2024Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
181000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
271413000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
18000
CY2023Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
14000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3974000
CY2023Q1 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
345000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-32038000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
243726000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
897000
CY2023Q2 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
14000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4153000
CY2023Q2 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
261000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
303000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-35178000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
213654000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
179250000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
246000
CY2024Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
35000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4873000
CY2024Q1 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
4000
CY2024Q1 glue Issuance Of Common Stock Pursuant To The At The Market Sales Agreement
IssuanceOfCommonStockPursuantToTheAtTheMarketSalesAgreement
87000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-31968000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
152519000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
422000
CY2024Q2 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
35000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4502000
CY2024Q2 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
12000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
298000
CY2024Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
290000
CY2024Q2 glue Issuance Of Pre Funded Warrant Net Of Issuance Costs
IssuanceOfPreFundedWarrantNetOfIssuanceCosts
49710000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-30310000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
224671000
us-gaap Profit Loss
ProfitLoss
-62278000
us-gaap Profit Loss
ProfitLoss
-67216000
us-gaap Share Based Compensation
ShareBasedCompensation
9375000
us-gaap Share Based Compensation
ShareBasedCompensation
8127000
us-gaap Depreciation
Depreciation
3957000
us-gaap Depreciation
Depreciation
2542000
glue Accretion Of Discounts Premiums On Marketable Securities Net
AccretionOfDiscountsPremiumsOnMarketableSecuritiesNet
-1163000
glue Accretion Of Discounts Premiums On Marketable Securities Net
AccretionOfDiscountsPremiumsOnMarketableSecuritiesNet
-2680000
glue Gain Loss On Marketable Securities
GainLossOnMarketableSecurities
0
glue Gain Loss On Marketable Securities
GainLossOnMarketableSecurities
-131000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
24000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9000000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
337000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-1858000
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.95
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.36
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.36
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71233992
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
71233992
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49431922
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49431922
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2412000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-547000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4676000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-696000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1842000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-520000
us-gaap Defined Benefit Plan Other Changes
DefinedBenefitPlanOtherChanges
29000
us-gaap Defined Benefit Plan Other Changes
DefinedBenefitPlanOtherChanges
0
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-768000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
9201000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
3241000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-65932000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-48730000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3406000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15693000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
62000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
130027000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
67824000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
45631000
glue Proceedsfrommaturityofmarketablesecurities
Proceedsfrommaturityofmarketablesecurities
82128000
glue Proceedsfrommaturityofmarketablesecurities
Proceedsfrommaturityofmarketablesecurities
76700000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-51305000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
38876000
glue Net Of Underwriting Discount On Issuance Of Common Stock
NetOfUnderwritingDiscountOnIssuanceOfCommonStock
29000
glue Underwriters Discount On Underwritten Public Offering Cost
UnderwritersDiscountOnUnderwrittenPublicOfferingCost
3000000
glue Proceeds From Underwritten Public Offering Cost
ProceedsFromUnderwrittenPublicOfferingCost
47001000
glue Proceeds From Underwritten Public Offering Cost
ProceedsFromUnderwrittenPublicOfferingCost
0
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
50000000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
641000
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
667000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
915000
us-gaap Proceeds From Issuance Of Common Stock Dividend Reinvestment Plan
ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan
298000
us-gaap Proceeds From Issuance Of Common Stock Dividend Reinvestment Plan
ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan
303000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
98269000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1218000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18968000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8636000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
132681000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60190000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
113713000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51554000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
108847000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47027000
CY2024Q2 us-gaap Restricted Cash
RestrictedCash
4866000
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
4527000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
113713000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51554000
glue Reduction Of Right Of Use Assets For Lease Incentives Receivable
ReductionOfRightOfUseAssetsForLeaseIncentivesReceivable
0
glue Reduction Of Right Of Use Assets For Lease Incentives Receivable
ReductionOfRightOfUseAssetsForLeaseIncentivesReceivable
4644000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
235000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1438000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-428200000
us-gaap Net Income Loss
NetIncomeLoss
-62300000
us-gaap Net Income Loss
NetIncomeLoss
-67200000
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
262200000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65695095
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65695095
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49389931
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49389931
CY2024Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
270544000
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
236420000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
153426000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
7000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
75000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
153358000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
104365000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
15000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
68000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
104312000
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
49450000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
46047000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
16200000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12244000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33250000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33803000
CY2023Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
114000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
537000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
389000
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 glue Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
CY2024Q2 glue Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 us-gaap Depreciation
Depreciation
2060000
CY2023Q2 us-gaap Depreciation
Depreciation
1391000
us-gaap Depreciation
Depreciation
3957000
us-gaap Depreciation
Depreciation
2542000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5143000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7593000
CY2024Q2 glue Accrued Research And Development
AccruedResearchAndDevelopment
5665000
CY2023Q4 glue Accrued Research And Development
AccruedResearchAndDevelopment
5336000
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1951000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1671000
CY2024Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
12759000
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
14600000
CY2024Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
0
us-gaap Payments For Tenant Improvements
PaymentsForTenantImprovements
13000000
us-gaap Operating Lease Cost
OperatingLeaseCost
3249000
us-gaap Operating Lease Cost
OperatingLeaseCost
3983000
us-gaap Variable Lease Cost
VariableLeaseCost
2131000
us-gaap Variable Lease Cost
VariableLeaseCost
1128000
us-gaap Lease Cost
LeaseCost
5380000
us-gaap Lease Cost
LeaseCost
5111000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y2M12D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y7M6D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.098
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.098
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
108000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1871000
glue Cash Paid For Amount Included In Measurement Of Lease Liabilities
CashPaidForAmountIncludedInMeasurementOfLeaseLiabilities
1372000
glue Cash Paid For Amount Included In Measurement Of Lease Liabilities
CashPaidForAmountIncludedInMeasurementOfLeaseLiabilities
1790000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1000000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1500000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
61333597
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
61328282
glue Description Of Pre Funded Warrants
DescriptionOfPreFundedWarrants
A holder of a Pre-Funded Warrant may not exercise such Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the holder, up to 19.99%) of the number of shares of the Company’s common stock outstanding immediately after giving effect to such exercise. No pre-funded warrants have been exercised as of June 30, 2024
CY2024Q2 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
-0
us-gaap Payments Of Dividends
PaymentsOfDividends
0
us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2024Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
32333442
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
19646545
us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
0
CY2023Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
25000000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9394930
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.78
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4741000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2828540
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.53
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
235268
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.84
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
452633
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.99
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11535569
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.14
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1836000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
11535569
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
8.14
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
1836000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5353616
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y1M6D
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1598000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9375000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8127000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
300000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-30310000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-35178000

Files In Submission

Name View Source Status
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
0000950170-24-093296-index-headers.html Edgar Link pending
0000950170-24-093296-index.html Edgar Link pending
0000950170-24-093296.txt Edgar Link pending
0000950170-24-093296-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
glue-20240630.htm Edgar Link pending
glue-20240630.xsd Edgar Link pending
glue-ex10_1.htm Edgar Link pending
glue-ex31_1.htm Edgar Link pending
glue-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
glue-20240630_htm.xml Edgar Link completed